Share ownership BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 07/09/2024 am IST			5-day change	1st Jan Change
191.32 ^USD	-0.14%		-0.24%	+6.08%

05/09	Transcript : BeiGene, Ltd. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:00 AM
05/09	BeiGene Grants Share Options, RSUs under Incentive Plan	MT

Share class: BeiGene, Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	1,264,474,003	1,222,239,074 ( 96.66 %)	0	96.66 %

Major shareholders: BeiGene, Ltd.

Name	Equities	%	Valuation
Amgen, Inc. 19.53 %	246,269,426	19.53 %	3 096 M $
Capital Research & Management Co. (International Investors) 8.203 %	103,421,157	8.203 %	1 300 M $
John Oyler 6.069 %	76,515,076	6.069 %	962 M $
HHLR Advisors Ltd. 5.995 %	75,588,463	5.995 %	950 M $
Xiao Dong Wang 1.628 %	20,532,185	1.628 %	258 M $
Bosera Asset Management Co., Ltd. 1.192 %	15,032,800	1.192 %	189 M $
Capital International, Inc. 0.6644 %	8,376,845	0.6644 %	105 M $
GF Fund Management Co., Ltd. 0.6053 %	7,632,000	0.6053 %	96 M $
China Asset Management Co., Ltd. 0.2820 %	3,555,000	0.2820 %	45 M $
Donald Glazer 0.2156 %	2,718,464	0.2156 %	34 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Penghua Fund Management Co., Ltd. 6.339 %	7,293,081	6.339 %	131 M $
Wanjia Asset Management Co., Ltd. 4.489 %	5,165,056	4.489 %	93 M $
ICBC Credit Suisse Asset Management Co., Ltd. 4.042 %	4,650,382	4.042 %	83 M $
Bank of China Investment Management Co., Ltd. 2.640 %	3,037,160	2.640 %	55 M $
Bosera Asset Management Co., Ltd. 2.328 %	2,678,498	2.328 %	48 M $
Taiping Life Insurance Co. Ltd. (Investment Portfolio) 2.092 %	2,407,263	2.092 %	43 M $
Abu Dhabi Investment Authority (Investment Management) 2.092 %	2,407,263	2.092 %	43 M $
China International Capital Corp. Ltd. (Invt Management) 1.799 %	2,069,546	1.799 %	37 M $
GF Fund Management Co., Ltd. 1.640 %	1,887,243	1.640 %	34 M $
Yinhua Fund Management Co., Ltd. 1.318 %	1,516,272	1.318 %	27 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Baker Bros. Advisors LP 10.90 %	10,568,897	10.90 %	1 761 M $
Capital Research & Management Co. (International Investors) 7.231 %	7,013,568	7.231 %	1 168 M $
HHLR Advisors Ltd. (Cayman Islands) 5.338 %	5,176,906	5.338 %	862 M $
PRIMECAP Management Co. 5.141 %	4,986,289	5.141 %	831 M $
Baillie Gifford & Co. 3.796 %	3,681,949	3.796 %	613 M $
Temasek Holdings Pte Ltd. 3.108 %	3,014,171	3.108 %	502 M $
T. Rowe Price International Ltd. 2.343 %	2,272,822	2.343 %	379 M $
Fidelity Management & Research Co. LLC 1.698 %	1,647,156	1.698 %	274 M $
BlackRock Advisors LLC 0.9110 %	883,517	0.9110 %	147 M $
Capital International, Inc. 0.8817 %	855,134	0.8817 %	142 M $
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Amgen, Inc.	19.53%
Institutional	19.17%
Individuals	8.40%
Unknown	52.90%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	28.46%
Individuals	8.40%
Hong Kong	6.42%
China	3.12%
Switzerland	0.23%
United Kingdom	0.16%
Sweden	0.08%
Ireland	0.07%
Italy	0.03%
Norway	0.03%
Luxembourg	0.02%
Germany	0.01%
Malaysia	0.01%
Austria	0.01%
France	0.01%
New Zealand	0.01%
Denmark	0.01%
Japan	0.01%
Singapore	0.01%

Based on 1000 largest holdings

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,000

Sector

Biotechnology & Medical Research

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Share ownership BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Share class: BeiGene, Ltd.

Major shareholders: BeiGene, Ltd.

Breakdown by shareholder type

Geographical origin of shareholders

Company Profile